Company intelligence / Profile preview

Dermama Biotechnology

Laweyan, Central Java, Indonesia

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Dermama Biotechnology is advancing exosome-based and stem cell therapies for chronic and age-related diseases, with one of its exosome therapy candidates (EXOMSC-COV19) in advanced clinical trials for regenerative applications, including wound healing and tissue regeneration. They have a decade-long track record and collaborations with industry and academia[1][3][6][8].

Therapeutic areas: EndocrinologyRheumatologyOphthalmologyGastroenterologyDermatologyOtherNeurology
Modalities: Exosome-based therapyStem cell therapyCell therapyNanoparticle
Industry: Biotech

Drug pipeline

1 asset

EXOMETA

Preclinical

Partnerships

Collaborations with top research institutions and industry leaders (not specified)[1]

Beyond the preview

Go deeper on Dermama Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dermama Biotechnology.

Explore the full profile